PAHC
Phibro Animal Health Corporation · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 6.87K | $256,897 | +1 | n/a |
| Q2 2026 | 76 | -16 | 15.41M | $484.55M | +5 | −21 |
| Q1 2026 | 95 | +6 | 14.51M | $800.97M | +11 | −5 |
| Q4 2025 | 89 | +1 | 14.47M | $540.64M | +1 | n/a |
| Q3 2025 | 17 | +1 | 9.22M | $372.92M | +1 | n/a |
| Q2 2025 | 13 | +1 | 8.13M | $207.65M | +2 | −1 |
| Q1 2025 | 9 | 0 | 3.02M | $64.46M | +1 | −1 |
| Q4 2024 | 9 | -1 | 3.00M | $62.94M | n/a | −1 |
| Q3 2024 | 9 | -1 | 1.81M | $40.65M | n/a | −1 |
| Q2 2024 | 10 | n/a | 1.66M | $27.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 6.87K | New | $256,897 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wealth Enhancement Advisory… | $256,897 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 255 holders, 20.06M shares, $1.03B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
48.2% of class · View original SEC filing ↗